We would love to hear your thoughts about our site and services, please take our survey here.
Https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/kaira-et-al-2022.pdf
Https://clinicaltrials.ucsf.edu/trial/NCT04993677
Seagen trial is it the one using Avidimab or am I just imagining that ?
It’s either way interesting trial
Please could someone let me know
Link to full event - immune-oncology-conference-London 7-8 th of March
https://events.marketsandmarkets.com/immuno-oncology-conference-london/#agenda
Just wondering why it’s not mentioned ceo of Scancell
A novel redirecting antibody targeting SCLC
Lindy Durrant, Professor, Cancer Immunotherapy, University of Nottingham, UK 14:45 - 15:15
A little reminder
EuroBiotech Report—Novartis, Immunocore-Scancell, Wren A round, Novo and BioNTech
This was from fierce pharma 2019
https://www.fiercebiotech.com/biotech/eurobiotech-report-novartis-immunocore-scancell-wren-a-round-novo-and-biontech
This was on linked in
We would like to say a BIG thank you to the organisations that supported this year's Melanoma Patient Conference! Our event would not be possible without our brilliant sponsors.
A special shout out to the extremely generous companies who donated products for this year's delegate goodie bags. 💙
University of Oxford
Bristol Myers Squibb
Scancell Ltd
Novartis
Pierre Fabre Group
Immunocore
Skcin - The Karen Clifford Skin Cancer Charity
Hello Sunday
Little Soap Company - BCorp™
Popcorn Kitchen Ltd
The Ginger People® / Ginger People Group
Ultra Violette Skincare
Nursem
La Roche-Posay Laboratoire Dermatologique
Pip Organic
Ego Pharmaceuticals
From Marcus 2 other board
University of Hong Kong (HKUMed), found that PD-1-enhanced DNA vaccination can induce sustained virus-specific CD8+ T cell immunity in an AIDS monkey model
https://www.globaltimes.cn/page/202403/1307969.shtml
9.25 prof Sarah Danson author of a recent poster
Giving updates on recent melanoma trials
https://melanomafocus.org/wp-content/uploads/2024/02/MPC24-Virtual-Brochure-2024-1.pdf
This why Genmab are interested in Glymab and why this is a very exciting area to be in . Found this article easily explaining the concept of something that’s been years in research
Cracking the sugar code: Why the ‘glycome’ is the next big thing in health and medicine
https://theconversation.com/cracking-the-sugar-code-why-the-glycome-is-the-next-big-thing-in-health-and-medicine-97750
Why do we care about glycans?
In the future, it is likely that analysis of an individual’s glycans will be used to predict our risk for developing diseases like rheumatoid arthritis, cancer or even food allergies. This is because glycome alterations can be specifically tied to particular disease states. Also, biological processes like aging are linked to inflammation in our glycome. It remains to be tested if reversing these changes can help prevent disease, or even slow aging – an intriguing possibility.
Along with DNA, proteins, and fats, glycans are one of the four major macromolecules essential for life. Of these four, glycans are the final arbiters of how our cells behave.
https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c01069
Tomorrow there will be anxious patients and interested clinicians seeing what is happening in drug trials
wish prof Sarah Danson. Good luck with her presentation.
it. This is ground, breaking scientific breakthroughs that Lindy Durant has been working on amost of her life, and I wish this “ beefed up team “ the best of luck, along with the patients who put their faith in going into Scancell trials
DYOR
A little of todays research showing what a little positive news can do to a share price
TIL therapy — a first of its kind — offers new hope for patients with metastatic melanoma
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
https://www.roswellpark.org/cancertalk/202402/til-therapy-first-its-kind-offers-new-hope-patients-metastatic-melanoma
Amtagvi also received Orphan Drug, Regenerative Medicine Advanced Therapy, Fast Track, and Priority Review designations.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma
The share price of Iovance Biotherapeutics, Inc.
NasdaqGM: IOVA as of 27th of feb over a 12 months
Prev. Close 16.60
52 Wk. Low 3.21
52 Wk. High 17.60
*
Open 16.84
High 17.60
Low 16.15
Mkt Cap 4.87B
P/E (TTM) N/A
Div & Yield N/A & N/A
Cancer vaccines: 10 biotech companies that have changed the game
By Roohi Mariam Peter
10 mins
April 6, 2023
Updated
February 19,
https://www.labiotech.eu/best-biotech/cancer-vaccine-companies/
On this week , The Melanoma Patient Conference 2024Thursday 29th Feb- Friday 1st March 2024
https://melanomafocus.org
09:25am - 09:55am
Clinical Trials Update. Innovation and Progress (Professor Sarah Danson)
Prof Sarah Danson is involved in both Modi and Scancell melanoma trial ,
maybe a RNS this week before her presentation will give her more to talk about in 2024 ?
I have posted this before this is presentation is 2022 , after Poulam Patel prof Sarah Danson
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2023.41.16_suppl.2566
Re mass spectrometry
relevant scancell links
https://www.scancell.co.uk/citrullinated-glucose-regulated-protein-78-is-a-candidate-target-for-melanoma-immunotherapy
“This peptide is detected by mass spectrometry”
Results: We show the identification CD4 T cell responses to one citrullinated GRP78 epitope that are restricted through HLA DP*0401 and HLA-DR*0101 alleles. This peptide is detected by mass spectrometry in B16 melanoma grown in vivo and citrulline specific CD4 responses to two peptides spanning this epitope mediate efficient therapy of established B16 melanoma tumours in HHDII/DP4 (p
Cancer vaccine , how far have we come from curing cancer ,
written by Rahul Chowdhury and Lindy Durrant
February 2019
https://www.researchgate.net/publication/336421539_Cancer_vaccine_how_far_are_we_from_curing_cancer
Cites Catherine Wu .
Would we all agree Scancell have made gigantic steps since then ?
Looks like star price is improving
https://www.local.gov.uk/sites/default/files/documents/34.2_Probity_in_Planning_04.pdf
Morning all in all , I believe the scancell team are doing an excellent job at establishing an experiences commercial team around their groundbreaking science . the new auditors are another wheel in the cog . The well documentented delays were forgivable if it happened once , however the second delay . was totally unprofessional and must have placed a strain on an important relationship . So the change was I believe necessary .
we know the above fiasco resulted in a share price decline . that's bumped around 11-12p with an astonishing spread of 14 % what the views on this ?
BOJO excellent post . The Scancell team and Lindy Durrant are showing no signs of being wall flowers in the pharma stakes . Hopefully the dance card will be full of potential partners
Best of luck to one and all . Especially to all the patients x
Yes your correct Chester fast track approval we hope by the FDA . Am I correct in thinking Lindy said trials are going to be conducted in USA . Hopefully the recruitment in the trials will be speeding up with the melanoma focus conference . Good luck to one and all
Markus2 gave heads up on this from other board . here is the link
https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor
Thinking aloud I wonder if Merck and Moderna will carry on with the trial because of the following :
A very expensive trial ? ! Very complicated!
The genetic aberrations of each individual patient with cancer is different, which creates a challenge for the development of therapeutic cancer vaccines. One approach is to characterize the tumor from each individual, so that the vaccine can be tailored precisely for that person in order to be better targeted. This approach is difficult to scale up, takes more time and results in higher cost. The alternative is to develop off-the-shelf vaccines, but the challenge is how to make them sufficiently targeted and effective across a wide range of individuals. The pros and cons of these two approaches will be discussed"